WO2011074765A2 - Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie - Google Patents

Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie Download PDF

Info

Publication number
WO2011074765A2
WO2011074765A2 PCT/KR2010/006079 KR2010006079W WO2011074765A2 WO 2011074765 A2 WO2011074765 A2 WO 2011074765A2 KR 2010006079 W KR2010006079 W KR 2010006079W WO 2011074765 A2 WO2011074765 A2 WO 2011074765A2
Authority
WO
WIPO (PCT)
Prior art keywords
fermented
fermentation
obesity
hyperlipidemia
extract
Prior art date
Application number
PCT/KR2010/006079
Other languages
English (en)
Korean (ko)
Other versions
WO2011074765A3 (fr
Inventor
김호준
구병수
정명준
서재구
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Publication of WO2011074765A2 publication Critical patent/WO2011074765A2/fr
Publication of WO2011074765A3 publication Critical patent/WO2011074765A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A23L2/382—Other non-alcoholic beverages fermented
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Obesity is a metabolic disorder caused by an imbalance between calorie intake and consumption and is defined as an increased state of adipose tissue (Kopelman PG. And Stock MJ.). Obesity affects all age groups, especially in older adults. In addition, the fact that obesity can cause serious diseases such as hyperlipidemia, diabetes, cholelithiasis, and cardiovascular diseases such as arteriosclerosis and hypertension, is considered as a disease beyond obesity and metabolic disorders or risk factors of the disease. Family Medicine, 1994, 15 (7), 401-410; Journal of the Korean Academy of Family Medicine, 1992, 13 (4), 344], it is known that the risk of adult disease due to obesity is three to six times higher than that of normal people.
  • the main cause of obesity is the inability to control food intake by itself and due to excessive food supply, the amount of energy consumed is continuously excessive compared to the energy consumed.
  • Therapeutic drugs used in pharmacotherapy include digestive absorption inhibitors, anti-absorption inhibitors, or metabolic accelerators, but these drugs can put a burden on the human body and cause digestive problems.
  • a fat absorption blocker has the effect of blocking the absorption of fat in the digestive tract, but there are various side effects such as diarrhea in the digestive system, so only limited use is possible, and weight loss agents due to psychotropic drugs Heart and circulatory side effects and side effects when taken at the same time with other drugs can not be used without a doctor's prescription.
  • the present inventors have tried to find a drug that shows the therapeutic effect of obesity and hyperlipidemia from various herbal medicines derived from plants, which have been ingested for a long time and are guaranteed stability, and improve the absorption rate of such drugs in vivo and anti-obesity and anti-hyperlipidemia of the drug. While trying to find a method for maximizing efficacy, the present invention was completed by discovering drugs that exhibit anti-obesity and anti-hyperlipidemic effects and finding a method that can ensure the absorption and stability of such drugs in vivo.
  • the present invention relates to a composition for the prevention and treatment of obesity or hyperlipidemia, including the herbal medicine fermented product or extract of the fermented product as an active ingredient.
  • the present invention relates to a health food for the prevention and treatment of obesity or hyperlipidemia, and a pharmaceutical composition for the prevention and treatment of obesity or hyperlipidemia, including the herbal medicine fermented product or extract of the fermented product as an active ingredient.
  • the heart of the mulberry is mulberry ripe mulberry fruit
  • Audi has the effect of nourishing tonic that the hair is black when eaten a lot and gradually turns red from blue to purple to black.
  • It is known as a medicine that does not grow old because it makes blood very clean.It helps the liver and kidneys to treat bleeding, which helps to treat the small thirst (diabetes) caused by depletion of the essence, dry mouth, dry tongue and lack of adultery. It is effective for dizziness and insomnia. It is also known as a medicine that is effective in constipation and softens the intestines, which leads to lack of blood.
  • the medicine consisting of phalanges, creation, heartache will be named Samjeonghwan.
  • the present invention relates to a composition for the prevention and treatment of obesity or hyperlipidemia comprising the phalanx, phalanx, extract, fermented extract of fermented products, or as an active ingredient, the weight of the creation, phalanges, and loser is specifically limited However, preferably when the weight of the creation is set to 10, the weight of the phalanges may include 8 to 12, the weight of the heartache 18 to 22 may include the medicine.
  • the present invention converts the drug into a low-molecular substance that is easily absorbed by human cells through a fermentation process or by additionally generating a useful material for the human body by decomposing organic substances using enzymes that microorganisms have during fermentation. Not only did it significantly increase obesity efficacy, it could also perform intestinal immunity and detoxification functions.
  • the strain used to prepare the fermentation is isolated from the strains occupying the dominant species in the fermentation, Bifidobacterium longum (Bifidobacterium longum) and Bifidobacterium breve (Bifidobacterium breve) It may be a microorganism selected from the group consisting of.
  • the fermented product may be used as it is, and the fermented product may be extracted to provide a composition for the prevention and treatment of obesity or hyperlipidemia containing the extract of the fermented product as an active ingredient.
  • a mixed solvent having a mixing ratio, preferably methanol, may be used, and the solvent may be 5 to 100%, preferably 80 to 100%.
  • the extraction time may be hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction, preferably hot water extraction for 1 hour to 48 hours, preferably 12 hours to 36 hours, and the hot water extraction temperature is not particularly limited. Preferably it can be extracted at 40 to 80 °C, more preferably 50 to 70 °C, the extraction may be carried out repeatedly. In the extraction time and temperature, the extraction time can be reduced by increasing the extraction temperature, but excessively high temperature can destroy useful bacteria in fermented medicinal herbs to reduce the absorption rate of the medicament, Substance generation and intestinal immunity and toxin removal may be reduced. If the extraction temperature is too low, the extraction time increases and there is a problem that the active ingredient of the drug may not be completely extracted. The extract can be cooled, filtered and concentrated under reduced pressure to obtain an extract usable in the present invention.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of obesity or hyperlipidemia, including the phalanx, the production, the fermented product including the loser or extract of the fermented product as an active ingredient.
  • Carriers, excipients and diluents which may be included in the pharmaceutical composition comprising fermented products or extracts of fermented products include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, for example, starch, calcium carbonate, in the fermentation or extract of the fermentation product. Prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the preferred dosage of the fermentation or extract of the fermentation of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the fermentation product or the extract of the fermentation product of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg, but the dosage is changed depending on the condition of the patient. You may. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • Fermentation products or extracts of the fermentation products of the present invention can be used in a variety of health foods and beverages for the prevention and treatment of obesity or hyperlipidemia.
  • Examples of the food to which the present fermented product or extract of the fermented product can be added include various foods, beverages, gums, teas, vitamin complexes, and health foods.
  • Fermented product or extract of the fermented product of the present invention has little toxicity and side effects, so can be used with confidence even for long-term use for the purpose of prevention. Fermentation products or extracts of the fermentation products of the present invention may be added to food or beverage.
  • the amount of the fermentation product or the extract of the fermentation product in the food or beverage may be added to 0.01 to 50% by weight of the total food weight, the health beverage is 0.02 to 30 g, preferably 0.3 to 10 g based on 100 ml Can be added.
  • the health beverage of the present invention is not particularly limited to other ingredients except for containing the fermented product or extract of the fermented product as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the fermented products or extracts of the fermented products of the present invention include various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, colorants and neutralizing agents (cheese, chocolate, etc.), pectic acid and its Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
  • the fermentation products or extracts of the fermentation products of the present invention may contain the flesh for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the fermentation product or extract of the fermentation product.
  • the present invention provides a composition for the prevention and treatment of obesity or hyperlipidemia, containing the fermentation product of herbal medicine or extract of the fermentation product including phalanx, phalanx, heartache as an active ingredient.
  • the composition of the present invention will not only be excellent in the effects of anti-obesity and anti-hyperlipidemia, but also can be used as a medicine and health food using it because of its excellent safety in vivo absorption and no toxicity or side effects.
  • Figure 2 is a graph of quantitative evaluation of the results of observing the expression of PPAR-r and CEBPa, adifferentiation-related genes in 3T3-L1 cells by real time PCR, and the UCP-2 protein associated with heat generation. The most pronounced results were obtained at high doses of FH2.
  • Figure 4a shows the change in body weight of the normal group fed normal feed (normal), obesity-induced group fed high fat feed (HFD) and obese + samjeonghwan group fed high fat feed and fermented samjunghwan (HFD + SJH) .
  • Figure 4b shows the heart, spleen and kidney of the normal group fed normal feed (normal), the obesity-induced group fed high fat feed (HFD) and the obesity + samjunghwan group (HFD + SJH) fed high fat feed and fermented samjunghwan , Liver, epididymal fat, and abdominal visceral fat were measured.
  • normal normal
  • HFD obesity-induced group fed high fat feed
  • HFD + SJH obesity + samjunghwan group
  • Figure 4c shows normal triglycerides in the normal group fed normal feed, obesity-induced group fed high fat feed (HFD), and obese + samjeonghwan group fed high fermented samjunghwan (HFD + SJH). It shows the difference between high density lipoprotein and low density lipoprotein in blood.
  • HFD obesity-induced group fed high fat feed
  • HFD + SJH obese + samjeonghwan group fed high fermented samjunghwan
  • Figure 5 shows a microbial detection photograph for each medium.
  • Figure 6 shows a microscopic microscope image of each medium.
  • Figure 8 shows the pH change of the fermentation strains during the total fermentation period of three fermentation of three fermentation of three fermentation of three fermentation of three fermentation of three fermentation, three fermentation of Lactobacillus plantarum P23, three fermentation of Yeast DSII, three fermentation of Lactobacillus plantarum P23 and Yeast DSII.
  • FIG. 11 shows chromatograms (UV 254 nm analysis results) before and after fermentation of Samjunghwan medicinal products by lactic acid bacteria ( B. longum, E. faecium, P. pentosaceus) . It is not yet known which substances have the effect of inhibiting fat synthesis, but at least before and after fermentation, there are many active substance changes .
  • Figure 14 shows the ability to inhibit the differentiation of fat cells of Samjunghwan fermented with five lactic acid strains.
  • composition of the present invention that is not fermented was produced by grinding 600 g of each of the phalanges, phalanges, and made into juice by squeezing the freshener 1200 g into raw materials.
  • the fermented composition of the present invention is made by grinding 600 g of each of the phalanges, phalanges, and powder, and squeezed 1200 g of raw heartwood into juice. After fermentation in 35 days was prepared in a ring.
  • the pre-adipocyte 3T3 L-1 cells used in the experiment were purchased from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured in DMEM (Invitrogen, USA) medium containing 10% Fetal Bovine Serum (FBS; Invitrogen, USA) in a 37 ° C., 5% CO 2 incubator. To prevent contamination, 100 units / ml penicillin and 100 ug / ml streptomycin (Gibco / BRL, USA) were added as antibiotics. Subsequent passages were treated with Trypsin-EDTA (Gibco / BRL, USA). The medium was changed every 2-3 days.
  • adipocytes To differentiate into adipocytes, transfer to a 6-well plate (Corning, USA) in the number of 1 ⁇ 10 5 / well and exchange with a primary differentiation medium containing 10 ⁇ g / ml Insulin, 0.25 ⁇ M Dexamethasone, 0.5 mM IBMX Induce differentiation into adipocytes for 6 days in medium containing 5 ⁇ g / ml Insulin, a differentiation medium. The medium was replaced with fresh medium every two days. The concentration of the cells was treated by diluting 500 and 1000 times the fermentation and fermented Samjunghwan, respectively, to the cells.
  • PPAR-gamma, SREBP-1c and TNF-alpha genes involved in adipocyte differentiation were observed using real time PCR. After 24 hours, two concentrations of Samjunghwan and fermented Samjunghwan concentrates were differentiated into differentiated adipocytes. RNA was extracted from the cells using Trisol (Invitrogen, USA) to synthesize cDNA. PCR (Light cycler 480, Boeringer Manheim, Germany) was performed and the expression level of each gene was calculated with beta-actin.
  • White rats were divided into 6 rats in each group (normal group, obesity-inducing group, obesity + samjung-hwan group).
  • Total cholesterol in blood was measured using A-CHO T-CHO kit. After mixing 3 ml of enzyme reagent in 20 ⁇ l of Serum, the solution was incubated at 37 ° C. for 5 minutes and absorbed at 500 nm within 60 minutes.
  • Blood triglycerides were measured using Asan Pharmaceutical's Triglyceride Test Kit (Cleantech TG-S). After mixing 3 ml of enzyme reagent in 20 ⁇ l of Serum, the solution was incubated at 37 ° C. for 10 minutes, and the absorbance was measured at 550 nm within 60 minutes.
  • HDL-Cholesterol High Density Lipiprotein
  • Blood HDL was measured using Aesque Pharmaceutical's Ezediel Colletase Test Solution (HDL-CHO) kit. After mixing 3 ml of enzyme reagent in 200 ⁇ l of Serum, the solution was incubated at 37 ° C. for 5 minutes, and the absorbance was measured at 500 nm within 60 minutes.
  • HDL-CHO Aesque Pharmaceutical's Ezediel Colletase Test Solution
  • LDL-Cholesterol Low Density Lipiprotein
  • Microorganism analysis other than lactic acid bacteria of the present invention was carried out in accordance with the 2008 Food Code, Health Functional Food Code, Korea Pharmacopoeia, was prepared by diluting 1g of fermented herbal medicine Samjunghwan powder in 9ml of sterilized anaerobic water.
  • the contamination detection medium was 37 ° C. for 48 hours using Plate Count Agar (PCA), Trypic Soy Agar (TSA), Nutrient Agat (NA), Blood Plate Agar (BAP), SBM, and KF. Cultures (42 ° C for SBM) and fungi were cultured in aerobic culture at 25 ° C for 5 days using DRBC Agar and Potato Dextrose Agar (PDA) as contamination detection media.
  • PCA Plate Count Agar
  • TSA Trypic Soy Agar
  • NA Nutrient Agat
  • BAP Blood Plate Agar
  • SBM Blood Plate Agar
  • KF KF.
  • Cultures (42 ° C for SBM) and fungi were cultured in aerobic culture at 25 ° C for 5 days using DRBC Agar and Potato Dextrose Agar (PDA) as contamination detection media.
  • PDA Potato Dextrose Agar
  • For detection of pathogens Oxford agar, MYP, Macconky agar, and MSA were used for the detection of path
  • the number of bacteria was measured by comparing with the standard graph of each strain.
  • the standard graph for each strain was cultured for each strain to measure the number of bacteria present in 1 mL, and DNA was extracted using the strain present in 1 mL. After dilution by dilution method, real-time PCR using SYBR Green I was performed, and a graph was used as data.
  • 0.1g Samjunghwan powder was dissolved in Lysozyme, and DNA was extracted using a DNA preparation kit.
  • Table 5 Table 6
  • Table 7 shows the PCR conditions and primers for eight strains of Bifidobacterium longum, Bifidobacterim bifidum, Bifidobacterium breve, Lactobacillus acidophilus, Escherichia coli, Salmonella spp., Candida albicans, Bacteroides fragilis, Table 8 And Figure 7 shows the amount of each strain present in the Samjunghwan powder.
  • Table 8 Amount of each strain present in Samjunghwan powder division Amount present in Samjunghwan Powder Bifidobacterium longum 2.10E + 04 Lactobacillus acidophilus 3.00E + 05 Bifidobacterium bifidum 4.00E + 04 Bifidobacterium breve 1.10E + 03 Escherichia coli 6.00E + 02 Salmonella spp. 1.30E + 02 Candida albicans 4.60E + 06 Bacteroides fragilis 5.00E + 01
  • CP value was converted to the number of bacteria using the standard curve measured previously.
  • the lactic acid bacteria fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, fermented, Yeast fermentation was confirmed that the fermentation effect is superior to natural fermentation.
  • the fermented Samjeong hwan, fermented Samjeong hwan, yeast fermented Samjeong hwan were not fermented because the fermented samjeong hwan was more effective than the fermented Samjeong hwan. It can be seen that the anti-obesity effect is superior to the ring.
  • the fastest fermentation of the lactic acid bacterium fermented Samjung-hwan is performed smoothly within one week and almost all reducing sugars are consumed in the second week, and the fermented Samjeong-hwan and yeast fermented Samjeong-hwan are It showed a pattern of consuming sugar at about the same speed, and fermentation proceeded rapidly after 3 weeks of rapid consumption of sugar.
  • the fermented Samjeong hwan, fermented Samjeong hwan, yeast fermented Samjeong hwan were not fermented because the fermented samjeong hwan was more effective than the fermented Samjeong hwan. It can be seen that the anti-obesity effect is superior to that, among which the lactic acid bacteria fermented Samjung-hwan shows a good fermentation effect within the shortest time, and thus the anti-obesity effect is also excellent.
  • the strains used for fermentation are Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum P23, Enterococcus faecium, Pediococcus pentosaceus.
  • L. plantarum P23 and P. pentosaceus are plant lactic acid bacteria isolated from Kimchi.
  • Lactobacillus spawn was incubated at a concentration of about 10 7 cfu / ml (1%) and incubated at 37 ° C. for up to 61 hours.
  • Some of the fermentation broth in the middle of fermentation and after fermentation were removed by lactic acid bacteria through centrifugation, and pH change was measured over time using supernatant. In addition, the supernatant before and after fermentation was analyzed for chromatogram change using
  • Vitamin B6 0.5 mg
  • composition ratio of the vitamin and mineral mixture is a composition suitable for a relatively healthy food in a preferred embodiment
  • the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.
  • composition containing the fermentation product including the creation of the present invention, phalanges, lettuce, as an active ingredient can be used as a pharmaceutical or health food for the prevention and treatment of obesity and hyperlipidemia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition incluant un matériel fermenté pour la médecine orientale ou un extrait du matériel fermenté au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie, et plus particulièrement, une composition incluant une matière fermentée pour la médecine orientale contenant Atractylodes lancea, Lycium barbarum L. et Morus alba L., ou un extrait du matériel fermenté au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité et de l'hyperlipidémie. Selon la présente invention, le matériel fermenté pour la médecine orientale ou l'extrait du matériel fermenté présente non seulement d'excellents effets contre l'obésité et l'hyperlipidémie, mais également une absorbance biologique et une biocompatibilité satisfaisantes, ce qui permet de l'employer dans des produits médicaux et des alicaments.
PCT/KR2010/006079 2009-12-15 2010-09-08 Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie WO2011074765A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0124769 2009-12-15
KR20090124769 2009-12-15

Publications (2)

Publication Number Publication Date
WO2011074765A2 true WO2011074765A2 (fr) 2011-06-23
WO2011074765A3 WO2011074765A3 (fr) 2011-08-11

Family

ID=44167793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006079 WO2011074765A2 (fr) 2009-12-15 2010-09-08 Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie

Country Status (2)

Country Link
KR (1) KR101076223B1 (fr)
WO (1) WO2011074765A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109430853A (zh) * 2018-12-28 2019-03-08 齐鲁工业大学 一种有机枸杞酵素及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013032102A1 (fr) * 2011-09-01 2013-03-07 한국한의학연구원 Produit gui pi tang fermenté et application associée
KR101593124B1 (ko) 2015-09-11 2016-02-11 황찬우 지장수 제조장치
KR102293771B1 (ko) * 2018-12-18 2021-08-26 농업회사법인 주식회사 이비채 한약재 발효물 및 염지하수를 이용한 음료의 제조방법 및 이의 제조방법으로 제조된 음료

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020714A (ko) * 2001-09-04 2003-03-10 (주)바이오뉴트리젠 지골피 추출물을 포함하는 혈중 지질농도 저하용 조성물
KR20050013370A (ko) * 2003-07-28 2005-02-04 김영찬 한약재를 이용한 비만 치료 조성물
KR100562467B1 (ko) * 2003-07-18 2006-03-17 주식회사 싸이클로젠 항비만 치료제
KR20090109020A (ko) * 2008-04-14 2009-10-19 동화약품주식회사 정향 추출물을 유효성분으로 함유하는 고지혈증 치료시유발되는 간손상 치료용 약학조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100733336B1 (ko) 2005-12-22 2007-06-29 한국 한의학 연구원 갈근 또는 갈화 추출물의 발효물을 함유하는 비만 또는고지혈증의 예방 또는 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020714A (ko) * 2001-09-04 2003-03-10 (주)바이오뉴트리젠 지골피 추출물을 포함하는 혈중 지질농도 저하용 조성물
KR100562467B1 (ko) * 2003-07-18 2006-03-17 주식회사 싸이클로젠 항비만 치료제
KR20050013370A (ko) * 2003-07-28 2005-02-04 김영찬 한약재를 이용한 비만 치료 조성물
KR20090109020A (ko) * 2008-04-14 2009-10-19 동화약품주식회사 정향 추출물을 유효성분으로 함유하는 고지혈증 치료시유발되는 간손상 치료용 약학조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109430853A (zh) * 2018-12-28 2019-03-08 齐鲁工业大学 一种有机枸杞酵素及其制备方法

Also Published As

Publication number Publication date
KR101076223B1 (ko) 2011-10-26
KR20110068889A (ko) 2011-06-22
WO2011074765A3 (fr) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2015122717A1 (fr) Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation
KR102077715B1 (ko) 비만 억제 활성을 갖는 락토바실러스 파라카제이 ao356 균주 및 이를 포함하는 비만 개선 또는 치료용 조성물
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2018093238A2 (fr) Composition comprenant en tant qu'ingrédient actif une souche présentant une excellente aptitude à produire de l'acide formique pour prévenir ou traiter l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2018062914A1 (fr) Nouveau lactobacillus sakei et composition le comprenant
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2011162523A2 (fr) Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci
WO2020116962A1 (fr) Composition de prévention, d'amélioration, ou de traitement du diabète, comprenant le produit de fermentation de bactéries acide lactique d'extrait de paeonia lactiflora comme ingrédient actif
WO2012033378A2 (fr) Composition comprenant un extrait de cudrania tricuspidata et de coix lachryma-jobi ayant une activité anti-obésité et un effet d'abaissement du taux de sucre dans le sang, et son utilisation
WO2010087577A2 (fr) Utilisation d'extrait de thymus capitatus, d'extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
KR20140120285A (ko) 발효 청미래덩굴 잎 및 이의 추출물
WO2011074765A2 (fr) Composition incluant un matériel fermenté pour la médecine orientale au titre de principe actif dans le traitement prophylactique et thérapeutique de l'obésité ou de l'hyperlipidémie
WO2016072655A1 (fr) Composition pour améliorer, traiter ou prévenir la constipation comprenant un produit fermenté renfermant des bactéries lactiques de graines de cassia comme ingrédient efficace, et son procédé de préparation
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2012134172A2 (fr) Composition contenant, comme ingrédient actif, une fraction d'acétate d'éthyle de schisandra chinensis baill, ou wuweizisu c séparée de la fraction, pour prévenir ou traiter l'obésité
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2020045972A1 (fr) Souche de lactobacillus fermentum mg4231 ou de lactobacillus fermentum mg4244 dérivé du corps humain, ayant une activité anti-obésité, et composition la comprenant
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
WO2013022178A1 (fr) Composition pour prévention et traitement de l'obésité contenant un principe actif sous la forme d'un extrait de préparation végétale mélangée à base de lonicera japonica et d'aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10837762

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10837762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10837762

Country of ref document: EP

Kind code of ref document: A2